Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease

Gut

Volumn 48, Issue 5, 2001, Pages 642-646

  Cuffari, C ^a   Hunt, S ^a   Bayless, T ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Azathioprine; Inflammatory bowel disease; Metabolites

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; DRUG METABOLITE; MERCAPTOPURINE; PREDNISONE; TIOGUANINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CORRELATION FUNCTION; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; ERYTHROCYTE; FEMALE; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LEUKOPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; REMISSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; REFERENCE VALUES; REMISSION INDUCTION; THIOGUANINE; TREATMENT OUTCOME;

EID: 0035037706     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.48.5.642     Document Type: Article

References (26)

1. Azathioprine and 6-mercaptopurine in Crohn's disease: A meta-analysis
2. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease
3. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease
4. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease
5. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study
6. 6-Thioguanine induced DNA damage as a determinant of cytotoxicity in cultured hamster ovary cells
7. The clinical pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia
8. The pharmacology of azathioprine
9. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration
10. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia
11. Concurrent unilateral chromatid damage and DNA strand breaks in response to 6-thioguanine treatment
12. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
13. Altered mercaptopurine metabolism, toxic effects, and dosage requirements in a thiopurine methyl transferase deficient child with acute lymphoblastic leukemia
14. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease
15. 6-mercaptopurine in the management of inflammatory bowel disease: Short and long-term toxicity
16. 6-mercaptopurine metabolism in Crohn's disease correlation with efficacy and toxicity
17. Crohn's disease
18. The Crohn's disease activity index, its derivatives and the inflammatory bowel disease questionnaire: A review of instruments to assess Crohn's disease
19. European Cooperative Crohn's disease study (ECCDS): Results of drug treatment
20. Cyclosporin in severe ulcerative colitis refractory to steroid therapy
21. Optimizing and individualizing 6-MP therapy in IBD: The role of 6-MP metabolite levels and TPMT genotyping
22. 6-thioguanine levels versus white blood cell counts in guiding 6-mercaptopurine and azathioprine therapy
23. Mesalamine capsules for the treatment of active ulcerative colitis. Results of a controlled trial
24. 6-mercaptopurine metabolites tailored to achieve clinical responsiveness in paediatric IBD
25. The role of leukopenia in 6-mercaptopurine-induced remission of refractory Crohn's disease
26. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered